Antipsychotics inhibit TREK but not TRAAK channels

Biochemical and Biophysical Research Communications

Volumn 354, Issue 1, 2007, Pages 284-289

  Thümmler, Susanne ^a   Duprat, Fabrice ^a   Lazdunski, Michel ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Depression; Mental disorders; Neuroleptics; Schizophrenia; Two pore domain background potassium channels

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; ION CHANNEL; LOXAPINE; NEUROLEPTIC AGENT; PAROXETINE; PIMOZIDE; POLYUNSATURATED FATTY ACID; POTASSIUM CHANNEL; PROTEIN TRAAK; PROTEIN TREK; SULPIRIDE; TIAPRIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; HALLUCINATION; HUMAN; IC 50; MECHANICAL STRESS; MOUSE; NONHUMAN; PHENOTYPE; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REGULATORY MECHANISM; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ION CHANNEL GATING; MEMBRANE POTENTIALS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN;

MUS;

EID: 33846407581     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.199     Document Type: Article

References (27)

1. Saha S., Chant D., Welham J., and McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2 (2005) e141
2. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
3. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 (2005) 79-104
4. Lesage F., and Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels. Am. J. Physiol. Renal Physiol. 279 (2000) F793-F801
5. + channels. Anesthesiology 95 (2001) 1013-1021
6. Goldstein S.A., Bayliss D.A., Kim D., Lesage F., Plant L.D., and Rajan S. International Union of Pharmacology. LV. Nomenclature and molecular relationships of two-P potassium channels. Pharmacol. Rev. 57 (2005) 527-540
7. Kim D. Physiology and pharmacology of two-pore domain potassium channels. Curr. Pharm. Des. 11 (2005) 2717-2736
8. + channel. EMBO J. 17 (1998) 4283-4290
9. Duprat F., Lesage F., Patel A.J., Fink M., Romey G., and Lazdunski M. The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol. Pharmacol. 57 (2000) 906-912
10. Siegelbaum S.A., Camardo J.S., and Kandel E.R. Serotonin and cyclic AMP close single K+ channels in Aplysia sensory neurones. Nature 299 (1982) 413-417
11. + channel. EMBO J. 15 (1996) 6854-6862
12. + channel family. J. Biol. Chem. 275 (2000) 17412-17419
13. + channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors. J. Biol. Chem. 275 (2000) 28398-28405
14. + channel stimulated by arachidonic acid and polyunsaturated fatty acids. EMBO J. 17 (1998) 3297-3308
15. Heurteaux C., Lucas G., Guy N., El Yacoubi M., Thümmler S., Peng X.D., Noble F., Blondeau N., Widmann C., Borsotto M., Gobbi G., Vaugeois J.M., Debonnel G., and Lazdunski M. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat. Neurosci. 9 (2006) 1134-1141
16. + channel involved in neuroprotection and general anesthesia. EMBO J. 23 (2004) 2684-2695
17. Kennard L.E., Chumbley J.R., Ranatunga K.M., Armstrong S.J., Veale E.L., and Mathie A. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br. J. Pharmacol. 144 (2005) 821-829
18. + channels. EMBO J. 22 (2003) 5403-5411
19. Alfredsson G., Wiesel F.A., and Skett P. Levels of chlorpromazine and its active metabolites in rat brain and the relationship to central monoamine metabolism and prolactin secretion. Psychopharmacology (Berl.) 53 (1977) 13-18
20. Sunderland T., and Cohen B.M. Blood to brain distribution of neuroleptics. Psychiatry Res. 20 (1987) 299-305
21. Tsuneizumi T., Babb S.M., and Cohen B.M. Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol. Psychiatry 32 (1992) 817-824
22. Baldessarini R.J., Centorrino F., Flood J.G., Volpicelli S.A., Huston-Lyons D., and Cohen B.M. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9 (1993) 117-124
23. Aravagiri M., Marder S.R., Yuwiler A., Midha K.K., Kula N.S., and Baldessarini R.J. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 13 (1995) 235-247
24. Svendsen C.N., and Bird E.D. HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain. Psychopharmacology (Berl.) 90 (1986) 316-321
25. Komoroski R.A., Newton J.E., Karson C., Cardwell D., and Sprigg J. Detection of psychoactive drugs in vivo in humans using 19F NMR spectroscopy. Biol. Psychiatry 29 (1991) 711-714
26. Karson C.N., Newton J.E., Mohanakrishnan P., Sprigg J., and Komoroski R.A. Fluoxetine and trifluoperazine in human brain: a 19F-nuclear magnetic resonance spectroscopy study. Psychiatry Res. 45 (1992) 95-104
27. Jockers-Scherubl M.C., Bauer A., Godemann F., Reischies F.M., Selig F., and Schlattmann P. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int. Clin. Psychopharmacol. 20 (2005) 27-31